Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study

Vittorio Pengo, Amelia Ruffatti, Cristina Legnani, Sophie Testa, Tiziana Fierro, Francesco Marongiu, Valeria De Micheli, Paolo Gresele, Marta Tonello, Angelo Ghirarduzzi, Elisa Bison, Gentian Denas, Alessandra Banzato, Seena Padayattil Jose and Sabino Iliceto

Published e-Letters

Compose eLetter

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Vertical Tabs

  • High-risk Antiphospholipid Antibody Profile: Matter of the Number or Titer of Tests?

    Dear Editor,

    We read the study by Pengo et al. with great interest, which demonstrated that the incidence of first thrombosis in patients with high- risk antiphospholipid antibody (aPL) profiles is 5.3% per year (1). High- risk was defined as persistent "triple aPL-positivity", namely positive lupus anticoagulant (LA) test, anticardiolipin antibody (aCL) enzyme- linked immunosorbent assay (ELISA), and anti-β...

    Show More
    Conflict of Interest:
    None declared.